DP Diagnostic Products

Diagnostic Products Corporation (NYSE:DP) announced today that it has scheduled a conference call to discuss the Company's financial results of its second quarter 2005 on Monday, July 25, 2005, at 9 a.m. Eastern standard time (6 a.m. PST). The Company plans to release its financial results before the market opens on Friday. If you are interested in participating in the call, please call 800-260-6066 on the day of the conference, at least ten minutes prior to the conference in order for the operator to tie you into the call. The operator will ask you to identify the call with the company name Diagnostic Products-Jim Brill. An "instant replay" of the call will be available until August 4. If you would like to take advantage of this special service, you can access it via 800-839-6713 and the code: "7241305." It usually takes two hours following the conference to set up the recording. About Diagnostic Products Corporation Diagnostic Products Corporation, founded in 1971, is the global leader dedicated exclusively to immunodiagnostics. DPC's product menu includes over 75 immunoassays and more than 365 specific allergens and allergy panels. In addition, DPC addresses the chemistry and laboratory automation testing needs of its customers through partnerships with manufacturers of chemistry systems and reagents. The combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. DPC also designs and manufactures automated laboratory instrumentation, which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories in more than 100 countries. *Additional Company information can be found on DPC's website at www.dpcweb.com. Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include the effects of governmental or other actions relating to the FDA's decision that its Application Integrity Policy should be applied to the Company or relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings.